Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• An C, Zhang J, Chu H, et al. Study of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring EGFR mutation. Pathol Oncol Res. 2016;22(4):763–768.
   PubMed Web of Science ®Google Scholar
• Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(33):e11936.
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–861.
   PubMed Web of Science ®Google Scholar
• Janning M, Loges S. Anti-angiogenics: their value in lung cancer therapy. Oncol Res Treat. 2018;41(4):172–180.
   PubMed Web of Science ®Google Scholar
• Sandra A, Solenn B, Steinmetz C, et al. Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017;13:2515–2535.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328–335.
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001;20(1–2):79–86.
   PubMed Web of Science ®Google Scholar
• Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol. 2013;4(3):253–263.
   PubMedGoogle Scholar
• Aj S, Wa M, Today J. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015;51(4):223–229.
   PubMed Web of Science ®Google Scholar
• Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9:6075–6081.
   PubMed Web of Science ®Google Scholar
• Liu W, Xu J, Wang M, et al. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol. 2011;39(5):1213–1220.
   PubMed Web of Science ®Google Scholar
• Bai ZG, Zhang ZT. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. OTT. 2018;11:7077–7087.
   Web of Science ®Google Scholar
• Xu MD, Liu L, Wu MY, et al. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Oncogenesis. 2018;7(11):94.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. JCO. 2007;25(12):1539–1544.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Talento S, Mitra N, et al. Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous non-small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5):469–477.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e341S–e368S.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Yasunaga M, Goto K, et al. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer. 2010;116(19):4597–4604.
   PubMed Web of Science ®Google Scholar
• Peng Q-X, Han Y-W, Zhang Y-L, et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget. 2017;8(32):52813–52822.
   PubMedGoogle Scholar
• Feng J, Qin S. The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model. OTT. 2018;11:3047–3057.
   Web of Science ®Google Scholar
• Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res. 2009;15(10):3495–3502.
   PubMed Web of Science ®Google Scholar
• Wu M, Liu J, Hu C, et al. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer. IJN. 2018;13:8461–8472.
   Web of Science ®Google Scholar
• Orlhac F, Soussan M, Maisonobe JA, et al. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55(3):414–422.
   PubMed Web of Science ®Google Scholar
• Weber WA, Grosu AL, Czernin J. Technology insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nat Clin Pract Oncol. 2008;5(3):160–170.
   PubMedGoogle Scholar
• Li Y, Huang P, Peng H, et al. Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma. Cancer Manag Res. 2019;11:3469–3479.
   PubMed Web of Science ®Google Scholar
• Loo DT. In situ detection of apoptosis by the TUNEL assay: an overview of techniques. Methods Mol Biol. 2011;682:3–13.
   PubMedGoogle Scholar
• Chen X, Guan Z, Lu J, et al. Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models. J Cancer. 2018;9(7):1207–1217.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Liu W, Ahmad SA, et al. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol. 2001;28:94–104.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004;5(1):13–17.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. JCO. 2009;27(8):1227–1234.
   PubMed Web of Science ®Google Scholar
• Manzo A, Montanino A, Carillio G, et al. Angiogenesis inhibitors in NSCLC. Int J Mol Sci. 2017;18(10):2021.
   PubMed Web of Science ®Google Scholar
• Qiu H, Li J, Liu Q, et al. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle. 2018;17(10):1235–1244.
   PubMed Web of Science ®Google Scholar
• Inoue S, Hartman A, Branch CD, et al. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007;15(2):287–294.
   PubMed Web of Science ®Google Scholar
• Shibuya M. VEGF-VEGFR system as a target for suppressing inflammation and other diseases. Endocr Metab Immune Disord Drug Targets. 2015;15(2):135–144.
   PubMed Web of Science ®Google Scholar
• Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 1995;6(1):3–18.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359–371.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027.
   PubMed Web of Science ®Google Scholar
• Orleth A, Mamot C, Rochlitz C, et al. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. J Drug Target. 2016;24(1):80–89.
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhai E, Liao B, et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer. Oncotarget. 2017;8(7):11990–12002.
   PubMedGoogle Scholar
• Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24–40.
   PubMedGoogle Scholar
• Zhou K, Zhang JW, Wang QZ, et al. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice. Acta Pharmacol Sin. 2019;40(4):556–562.
   PubMed Web of Science ®Google Scholar
• Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002;87(7):694–701.
   PubMed Web of Science ®Google Scholar
• Sun CJ, Yang ZG, Zhou XP, et al. Non-small cell lung cancer evaluated by first pass dynamic contrast-enhanced 16-slice spiral CT: correlation of tumor vascularity with pathological characteristics. Zhonghua Zhong Liu za Zhi. 2007;29(6):429–433.
   PubMedGoogle Scholar
• Bao X, Wang M-W, Luo J-M, et al. Optimization of early response monitoring and prediction of cancer antiangiogenesis therapy via noninvasive PET molecular imaging strategies of multifactorial bioparameters. Theranostics. 2016;6(12):2084–2098.
   PubMed Web of Science ®Google Scholar
• Goggi JL, Bejot R, Moonshi SS, et al. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. J Nucl Med. 2013;54(9):1630–1636.
   PubMed Web of Science ®Google Scholar
• Van den Abbeele AD. The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(Suppl 2):8–13.
   PubMed Web of Science ®Google Scholar